Inventiva is a biopharmaceutical company focused on drugs targeting nuclear receptors, transcription factors and epigenetic modulators, with lead programs lanifibranor (NASH, systemic sclerosis) and odiparcil (various MPS indications). The company plans to use the proceeds to advance lanifibranor toward potential Phase III work and to fund odiparcil clinical studies in children and other MPS indications, plus discovery programs and corporate purposes. Net proceeds from the transaction are expected to provide a cash runway to mid-2020. Key upcoming milestones cited include carcinogenicity study results for lanifibranor by end-Q2 2018, Phase IIb readouts for lanifibranor in SSc (early 2019) and NASH (H2 2019), and odiparcil Phase IIa/Phase Ib results in 2019. Inventiva employs over 100 staff, owns R&D facilities near Dijon, and holds partnerships with Institut Curie, AbbVie and Boehringer Ingelheim.

Total raised

$44M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2018